In conclusion, we demonstrated that IL-6 levels are lower in MS patients having at least one C allele at position -174 of IL-6 gene, which in turn determined a reduced probability of IFNβ-related FLS. This evidence concerns the gene IFNB1 and myeloid sarcoma.